Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thymus Neoplasms 1Thymoma 1Sarcoma 1Hyperplasia 1Histologically-confirmed Malignancies 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adult Women With a New Diagnosis of Invasive Breast Cancer (Have Not Undergone Treatment) 1

Interventions

Cisplatin 12Cetuximab 9pembrolizumab 7Radiotherapy 7Fluorouracil 6Carboplatin 5Radiotherapy, Intensity-Modulated 4Nivolumab 4epacadostat 3Radiation 3Docetaxel 3Venlafaxine Hydrochloride 2Surveys and Questionnaires 2Panitumumab 2Paclitaxel 2Ketamine 2zimberelimab 1vandetanib 1tislelizumab 1temsirolimus 1ruxolitinib 1plerixafor 1nimotuzumab 1linrodostat 1fosbretabulin 1fluoromisonidazole 1fludarabine phosphate 1fludarabine 1elgemtumab 1ebselen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Head and Neck Neoplasms × alovudine × Clear all
NCT00894101 2018-07-20

Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation

University of California, Irvine

Phase 2/3 Withdrawn
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡